Nature Technology Corporation (NTC) is a technology-based service company, providing vector design, development and manufacturing (OEM) assistance to biotech and bio-pharmaceutical companies, government labs and academic researchers, world-wide. NTC is a privately owned company currently located in The University of Nebraska Technology Park in Lincoln, Nebraska, USA. NTC has acquired exclusive world rights to six issued US Patents, with many additional US and Interntional Patents pending. NTC’s mission is to provide essential platform technology and services for the construction, delivery, and expression of genes and genetic vaccines in living cells and organisms. NTC is dedicated to innovating, developing and providing cost-effective, generic solutions for safe, efficient human vaccination and therapy using non-viral as well as virus-derived systems for gene delivery.
Nature Technology Corporation (NTC) does not currently have an SEC registered investment opportunity. If you are an accredited investor and wish to invest in NTC or be kept informed concerning future registered or unregistered offerings, please send an email to:
Dr. Clague Hodgson, CEO:
hodgson@natx.com
